Investor Presentaiton

Investor presentation Full year 2018 Novo Nordisk has a strong leadership position within the growing diabetes care market Global diabetes care market by treatment class OAD GLP-1 Insulin Novo Nordisk Global diabetes care value market share Sanofi DKK billion 500 400 300 200 100 0 Nov 2008 Novartis J&J - Total market: CAGR¹ 15.2% Injectables: CAGR¹ 18.0% 30% 25% 20% 35.7%¹ 15% 15.7%¹ 10% 5% 11.6%¹ 0% Nov 2018 Nov 2008 1 CAGR for 10-year period OAD: Oral anti-diabetic Source: IQVIA MAT Nov, 2018 value figures changing diabetes Slide 30 - AstraZeneca Merck Eli Lilly - Takeda Boehringer Ingelheim 28% Source: IQVIA MAT Nov, 2018 value figures Nov 2018 novo nordisk

View entire presentation